32 results on '"Bolwell, Brian J."'
Search Results
2. Case report and review of resolved fusariosis
- Author
-
Helm, Thomas N., Longworth, David L., Hall, Geraldine S., Bolwell, Brian J., Fernandez, Bernard, and Tomecki, Kenneth J.
- Subjects
Chemotherapy -- Complications ,Fungi, Pathogenic ,Leukemia -- Complications ,Bone marrow -- Transplantation ,Health - Abstract
Fusariosis is an infection caused by fungi (of the Fusarium species) that are usually harmless. People whose immune systems are compromised (not working properly), frequently due to chemotherapy or during bone marrow transplantation, are most at risk for developing fusariosis. In these cases, the infection has often been fatal, as the fungus responsible was resistant to the antifungal medications used. A case is reported of a 59-year-old man with leukemia who developed fusariosis, but recovered. The primary symptoms were reddish skin spots, skin hemorrhages and pustules, anemia, and muscle weakness. Treatment included amphotericin B (an antifungal drug), and the patient's improvement coincided with the recovery of bone marrow function. The results are discussed with reference to other cases of fusariosis. It is concluded that rapid diagnosis and bone marrow recovery are important for survival of patients with fusariosis, and that with aggressive treatment the infection can be cured. (Consumer Summary produced by Reliance Medical Information, Inc.)
- Published
- 1990
3. Low-Dose Lenalidomide After Nonmyeloablative Allogeneic Hematopoietic Cell Transplantation With Bortezomib as Graft-Versus-Host Disease Prophylaxis in High-Risk Multiple Myeloma.
- Author
-
Khouri, Jack, Reu, Frederic, Majhail, Navneet S., Gerds, Aaron, Jagadeesh, Deepa, Dean, Robert, Sobecks, Ronald, Hamilton, Betty K., Pohlman, Brad, Hill, Brian T., Corrigan, Donna, Kalaycio, Matt, Bolwell, Brian J., and Liu, Hien D.
- Published
- 2019
- Full Text
- View/download PDF
4. Risk Factors for 30-Day Hospital Readmission following Myeloablative Allogeneic Hematopoietic Cell Transplantation (allo-HCT)
- Author
-
Bejanyan, Nelli, Bolwell, Brian J., Lazaryan, Aleksandr, Rybicki, Lisa, Tench, Shawnda, Duong, Hien, Andresen, Steven, Sobecks, Ronald, Dean, Robert, Pohlman, Brad, Kalaycio, Matt, and Copelan, Edward A.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HOSPITAL admission & discharge , *MEDICARE , *ANALYSIS of variance , *GRAFT versus host disease , *BONE marrow - Abstract
Patient readmission within 30 days from discharge has been perceived by the Centers for Medicare and Medical Services as an indicator of poor healthcare quality for specific high-cost medical conditions. Patients who undergo allogeneic hematopoietic cell transplantation (allo-HCT) are often being readmitted. Our study identified the risk factors for 30-day readmission among 618 adult recipients of myeloablative allo-HCT from 1990 to 2009. Two hundred forty-two (39%) of 618 patients (median age = 42 years [range: 18-66]) were readmitted a median of 10 days (range: 1-30) from their hospital discharge. Median duration of readmission was 8 days (range: 0-103). Infections (n = 68), fever with or without identified source of infection (n = 63), gastrointestinal complications (n = 44), graft-versus-host disease (GVHD) (n = 38), and other reasons (n = 29) accounted for 28%, 26%, 18%, 16%, and 12% of readmissions, respectively. During their index admission, patients who were subsequently readmitted had more documented infections (P < .001), higher hematopoietic cell transplantation comorbidity index (HCT-CI) (P < .01), total body irridiation (TBI)-based conditioning (P < .001), unrelated donor (P < .001), and peripheral stem cell (P = .014) transplantation. In multivariable analysis, HCT-CI (odds ratio [OR] = 1.78; 95% confidence interval [CI], 1.25-2.52), TBI-based preparative regimen (OR = 2.63; 95% CI, 1.67-4.13), and infection during admission for allo-HSCT (OR = 2.00; 95% CI, 1.37-2.92) predicted 30-day readmission. Thirty-day readmission itself was an independent predictor of all-cause mortality (hazard ratio [HR]Adj = 1.66; 95% CI, 1.36-2.10). Our data emphasize the importance of a risk-standardized approach to 30-day hospital readmission if it is used as a quality-of-care metric for bone marrow transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
5. Nonmyeloablative Second Transplants are Associated with Lower Nonrelapse Mortality and Superior Survival Than Myeloablative Second Transplants
- Author
-
Hill, Brian T., Bolwell, Brian J., Rybicki, Lisa, Dean, Robert, Kalaycio, Matt, Pohlman, Brad, Tench, Shawnda, Sobecks, Ronald, Andresen, Steven, and Copelan, Edward
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *HEALTH outcome assessment , *MEDICAL care , *PROGNOSIS , *GRAFT versus host disease - Abstract
Allogeneic hematopoietic stem cell transplantation (SCT) for patients who have previously undergone allogeneic or autologous SCT is potentially curative, but dangerous. To identify patient, disease, and treatment characteristics associated with outcome, we analyzed prognostic factors in 98 consecutive patients who underwent second transplants using allogeneic donors at the Cleveland Clinic between May 1987 and October 2008. Inclusion criteria included age ≥18 years, first SCT either autologous or allogeneic, and second SCT allogeneic. Patients whose second transplant was myeloablative (MA) had shorter survival (median 3.2 versus 14.7 months, P < .001) than patients whose second transplant was nonmyeloablative (NMA). In multivariable analysis, MA second transplant was associated with a higher risk of NRM (hazard ratio [HR] 2.01, P = 0.022) and death (HR 2.13, P = 0.002). Improved survival after NMA second transplant occurred primarily in patients without acute leukemia and when the first transplant was allogeneic. Among 17 patients transplanted within 3 months of first transplant, mortality was 100% and median survival was 2.3 months. MA transplantation within 3 months of prior SCT carries an unacceptably high rate of NRM. NMA second transplants were associated with substantially less NRM and despite a higher incidence of relapse, significantly improved survival compared to MA second transplants. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
6. High Disease Burden Is Associated with Poor Outcomes for Patients with Acute Myeloid Leukemia Not in Remission Who Undergo Unrelated Donor Cell Transplantation
- Author
-
Blum, William, Bolwell, Brian J., Phillips, Gary, Farag, Sherif S., Lin, Thomas S., Avalos, Belinda R., Penza, Sam L., Marcucci, Guido, Byrd, John C., Kalaycio, Matt E., Sobecks, Ronald M., Pohlman, Brad, Brown, Stacey, Elder, Patrick J., and Copelan, Edward A.
- Subjects
- *
GRAFT versus host disease , *CELL transplantation , *MYELOID leukemia , *ANEMIA - Abstract
Abstract: Results were analyzed for 48 consecutive patients with acute myeloid leukemia not in remission who underwent unrelated donor bone marrow or stem cell transplantation between 1991 and February 2003 at 2 transplant centers. Forty-six were adults with a median age of 32 years (range, 4-58 years). Forty-two were HLA-A, -B, and -DR matched with their respective donors, and 6 were mismatched at 1 of these loci. The conditioning regimen was myeloablative in all cases: busulfan/cyclophosphamide/etoposide in 34 patients, busulfan/cyclophosphamide in 10 patients, and total body irradiation based in 4 patients. Median follow-up for survivors was 540 days (range, 145-2716 days). Only patients with <5000 peripheral blood blasts per microliter at the time of transplantation survived 2 years (18% versus 0%; P = .003). Similarly, patients with <20% blasts in the marrow at the time of transplantation had superior 2-year survival compared with those who had ≥20% (33% versus 5%; P = .04). Patients with <20% blasts who had ≥3 prior therapies also fared poorly. Cause of death was more commonly treatment related rather than relapse related. This study confirms that patients with acute myeloid leukemia not in remission can achieve prolonged survival with myeloablative conditioning and unrelated donor cell transplantation. However, sustained survival occurs only in patients with a low disease burden at the time of unrelated donor stem cell transplantation, and patients with a high disease burden may benefit from added counseling regarding the high risk of death due to both treatment-related toxicities and disease relapse. [Copyright &y& Elsevier]
- Published
- 2006
- Full Text
- View/download PDF
7. Efficacy of Standard Dose R-CHOP Alternating With R-HDAC Followed by Autologous Hematopoietic Cell Transplantation as Initial Therapy of Mantle Cell Lymphoma, a Single-Institution Experience.
- Author
-
Sawalha, Yazeed, Hill, Brian T., Rybicki, Lisa A., Sun, Danyu, Dean, Robert M., Jagadeesh, Deepa, Hamilton, Betty K., Gerds, Aaron T., Sobecks, Ronald M., Andresen, Steven, Liu, Hien K., Majhail, Navneet S., Pohlman, Brad, Kalaycio, Matt E., Bolwell, Brian J., and Smith, Mitchell R.
- Published
- 2018
- Full Text
- View/download PDF
8. Conditional Long-Term Survival after Autologous Hematopoietic Cell Transplantation for Diffuse Large B Cell Lymphoma.
- Author
-
El-Asmar, Jessica, Rybicki, Lisa, Bolwell, Brian J., Kharfan-Dabaja, Mohamed A., Dean, Robert, Hamilton, Betty K., Hanna, Rabi, Jagadeesh, Deepa, Kalaycio, Matt, Pohlman, Brad, Sobecks, Ronald, Hill, Brian T., and Majhail, Navneet S.
- Subjects
- *
CELL transplantation , *B cells , *AUTOGRAFTS , *LYMPHOMAS , *PROGRESSION-free survival - Abstract
• Survival improves with longer time in remission after autologous transplant for DLBCL. • Mortality risk approaches that of the general population with time. • Older age at transplant and relapse are associated with overall mortality risk. Autologous hematopoietic cell transplantation (AHCT) is standard therapy for patients with chemosensitive, relapsed, diffuse large B cell lymphoma (DLBCL). We performed a retrospective cohort study to delineate subsequent (conditional) and relative survival in 371 adult patients with DLBCL who underwent AHCT between 2000 and 2014 and had survived for 1, 2, 3, or 5 years after transplant. The probability of overall survival at 10 years after AHCT was 62%, 71%, 77%, and 86%, respectively, for the 4 cohorts, whereas that of progression-free survival (PFS) was 55%, 65%, 72%, and 81%, respectively. The respective cumulative incidence of nonrelapse mortality (NRM) at 10 years after transplantation was 13%, 12%, 11%, and 8%, respectively. In multivariable analysis, older age was associated with greater mortality risk among all but 5-year survivors; relapse within the landmark time was associated with greater mortality risk in all groups. Older age and relapse within the landmark time were associated with worse PFS in all groups. Standardized mortality ratio (SMR) was significantly higher than an age-, gender-, and race-matched general population, with the magnitude of SMR decreasing as the landmark time increased (4.0 for 1-year, 3.0 for 2-year, 2.4 for 3-year, and 1.8 for 5-year survivors). Our study provides information on long-term survival and prognosis that will assist in counseling patients with DLBCL who have received AHCT. Survival improves with longer time in remission post-transplant, although patients continue to remain at risk for NRM, underscoring the need for continued vigilance and prevention of late complications. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
9. Higher Risks of Toxicity and Incomplete Recovery in 13- to 17-Year-Old Females after Marrow Donation: RDSafe Peds Results.
- Author
-
Pulsipher, Michael A., Logan, Brent R., Kiefer, Deidre M., Chitphakdithai, Pintip, Riches, Marcie L., Rizzo, J. Douglas, Anderlini, Paolo, Leitman, Susan F., Varni, James W., Kobusingye, Hati, Besser, RaeAnne M., Miller, John P., Drexler, Rebecca J., Abdel-Mageed, Aly, Ahmed, Ibrahim A., Ball, Edward D., Bolwell, Brian J., Bunin, Nancy J., Cheerva, Alexandra, and Delgado, David C.
- Subjects
- *
BONE marrow , *FEMALES , *OLD age , *BLOOD cells , *POSTOPERATIVE pain - Abstract
• Children commonly report pain (71%) and symptoms (59%) at 24 to 48 hours after bone marrow (BM) donation. • Older age and female sex are associated with higher levels of pain peri-BM donation. • Females age 13 to 17 years are at increased risk for grade 2 to 4 pain at 1 year after BM donation. • More than 20% of donors age 13 to 17 do not return to baseline pain level at 1 year after BM donation. Although donation of bone marrow (BM) or peripheral blood stem cells (PBSCs) from children to family members undergoing allogeneic transplantation are well-established procedures, studies detailing levels of pain, symptoms, and long-term recovery are lacking. To address this lack, we prospectively enrolled 294 donors age <18 years at 25 pediatric transplantation centers in North America, assessing them predonation, peridonation, and at 1 month, 6 months, and 1 year postdonation. We noted that 71% of children reported pain and 59% reported other symptoms peridonation, with resolution to 14% and 12% at 1 month postdonation. Both older age (age 13 to 17 years versus younger) and female sex were associated with higher levels of pain peridonation, with the highest rates in older females (57% with grade 2-4 pain and 17% with grade 3-4 pain). Multivariate analyses showed a 4-fold increase in risk for older females compared with males age <13 years (P <.001). At 1 year, 11% of 13- to 17-year-old females reported grade 2-4 pain, compared with 3% of males age 13 to 17 years, 0% of females age <13 years, and 1% of males age <13 years (P =.01). Males and females age 13 to 17 years failed to return to predonation pain levels at 1 year 22% and 23% of the time, respectively, compared with 3% and 10% in males and females age <13 years (P =.002). Our data show that females age 13 to 17 years are at increased risk of grade 2-4 pain at 1 year and >20% of females and males age 13 to 17 years do not return to baseline pain levels by 1 year after BM donation. Studies aimed at decreasing symptoms and improving recovery in older children are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2019
- Full Text
- View/download PDF
10. Comparative Effectiveness of Busulfan and Fludarabine versus Fludarabine and 400 cGy Total Body Irradiation Conditioning Regimens for Acute Myeloid Leukemia/Myelodysplastic Syndrome.
- Author
-
Mustafa Ali, Moaath, Abounader, Donna M., Rybicki, Lisa A., Yurch, Melissa A., Starn, Jamie, Ferraro, Christina, Winslow, Victoria, Hamilton, Betty K., Gerds, Aaron T., Liu, Hien, Dean, Robert, Hill, Brian T., Pohlman, Brad, Andresen, Steven, Hanna, Rabi, Kalaycio, Matt, Bolwell, Brian J., Majhail, Navneet S., and Sobecks, Ronald M.
- Subjects
- *
BUSULFAN , *FLUDARABINE , *IRRADIATION , *ACUTE myeloid leukemia , *RED blood cell transfusion - Abstract
Allogeneic hematopoietic cell transplantation conditioning regimen intensity has varied for patients with acute myeloid leukemia and myelodysplastic syndrome. A comparative effectiveness analysis was performed to assess outcomes of busulfan and fludarabine (BuFlu) versus those of fludarabine and 400 cGy total body irradiation (FluTBI) conditioning. Thirty-three subjects received BuFlu and 38 received FluTBI. The BuFlu group received more red blood cell transfusions ( P = .02) and had a longer time to platelet recovery ( P = .004). There were no differences between the regimens regarding incidence of acute or chronic graft-versus-host disease (GVHD), quality of life, or 2-year outcome estimates for relapse (48; 95% confidence interval [CI], 30 to 64 and 50; 95% CI, 33 to 65), nonrelapse mortality (29; 95% CI, 14 to 45 and 29; 95% CI, 15 to 44), relapse-free survival (27; 95% CI, 13 to 43 and 29; 95% CI, 16 to 44), and overall survival (35; 95% CI, 19 to 51; and 37; 95% CI, 22 to 52), respectively. These comparable outcomes have implications for health care resource utilization. Future prospective investigation comparing these regimens with larger patient cohorts and additional strategies to prevent relapse and limit toxicities as well as cost-effectiveness analyses are warranted. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
11. Daily Weight-Based Busulfan with Cyclophosphamide and Etoposide Produces Comparable Outcomes to Four-Times–Daily Busulfan Dosing for Lymphoma Patients Undergoing Autologous Stem Cell Transplantation.
- Author
-
Hill, Brian T., Rybicki, Lisa, Carlstrom, Kelley D., Jagadeesh, Deepa, Gerds, Aaron, Hamilton, Betty, Liu, Hien, Dean, Robert, Sobecks, Ronald, Pohlman, Brad, Andresen, Steven, Kalaycio, Matt, Bolwell, Brian J., and Majhail, Navneet S.
- Subjects
- *
CYCLOPHOSPHAMIDE , *BUSULFAN , *ETOPOSIDE , *LYMPHOMA treatment , *STEM cell transplantation , *DRUG efficacy , *DRUG side effects , *THERAPEUTICS - Abstract
High-dose busulfan (Bu) is an integral component of commonly used preparative regimens for both allogeneic and autologous transplantation. There is significant interest in comparing the efficacy and toxicity of administering Bu every 6 (Bu6) or every 24 hours (daily Bu). To facilitate a therapeutic dose-monitoring protocol, we transitioned from Bu6 to daily Bu dosing for patients with Hodgkin and non-Hodgkin lymphoma undergoing autologous stem cell transplantation (ASCT). Here, we retrospectively review outcomes of 400 consecutive eligible lymphoma patients who underwent ASCT from 2007 to 2013 with high-dose busulfan (Bu), cyclophosphamide (Cy), and etoposide (E). Bu was given at a fixed dose of either .8 mg/kg every 6 hours for 14 doses for 307 patients or a fixed dose of 2.8 mg/kg every 24 hours for 4 doses (days −9 through −6) for 93 patients who underwent transplantation after the transition from Bu6 to daily Bu was made. Toxicity was assessed using pulmonary and liver function tests (LFT) at specified time points before and after ASCT. Baseline patient and disease characteristics of patients dosed with Bu6 and daily Bu were similar. There was no significant difference in forced expiratory volume in 1 second or diffusing capacity of the lungs for carbon monoxide before and after transplantation in the Bu6 versus daily Bu cohorts. Changes in LFTs with daily Bu were not significantly different than those with Bu6. There were no differences in relapse, nonrelapse mortality, progression-free survival, or overall survival between Bu6 and Bu 24 administration schedules in univariable or multivariable analysis ( P ≥ .34). For a subset of 23 patients who had first-dose Bu levels measured, we observed significant variation in an median estimated cumulative area under the curve (AUC) of 17,568 µM-minute (range, 12,104 µM-23,084 µM-minute). In conclusion, daily Bu with Cy/E is more convenient than Bu6, has equivalent outcomes, and results in no increase in either hepatic or pulmonary toxicity. Consistent with previous reports, there is a significant range of Bu AUC levels, with a standard deviation of 13%. These data provide rationale for our prospective clinical trial of real-time therapeutic dose monitoring of Bu. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
12. Association of Socioeconomic Status with Outcomes of Autologous Hematopoietic Cell Transplantation for Multiple Myeloma.
- Author
-
Hong, Sanghee, Rybicki, Lisa, Abounader, Donna, Bolwell, Brian J., Dean, Robert, Gerds, Aaron T., Hamilton, Betty K., Hill, Brian T., Jagadeesh, Deepa, Kalaycio, Matt, Liu, Hien D., Pohlman, Brad, Sobecks, Ronald, and Majhail, Navneet S.
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MULTIPLE myeloma treatment , *RETROSPECTIVE studies , *SOCIOECONOMICS , *CAUCASIAN race , *PROGRESSION-free survival - Abstract
Autologous hematopoietic cell transplantation (AHCT) is standard therapy for eligible patients with multiple myeloma. Health care disparities can influence transplantation outcomes. However, the association of socioeconomic status (SES), a major indicator of health care disparities, with outcomes in patients with myeloma after AHCT has not been previously described. We analyzed 346 consecutive AHCT recipients with myeloma who underwent transplantation between 2003 and 2013 in this retrospective cohort study. Zip code of residence at the time of AHCT was obtained to assess annual household income based on 2010 US census data (median, $49,054; range, $16,546 to $127,313). SES groups were divided into < $45,000 (low; n = 120), $45,000 to $60,000 (middle; n = 116), and > $60,000 (high; n = 110). The low-income cohort had smallest portion of Caucasians (69% versus 89% versus 91%); otherwise, patient, disease, and transplantation characteristics were comparable among cohorts or different without significant patterns found. Median follow-up was 49 months. There was no difference among SES groups in overall survival, progression-free survival, nonrelapse mortality, or relapse in univariate and multivariable analysis. Similarly, SES was not associated with survival in a subset analysis of 303 patients who had survived for 1 year after transplantation. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
13. Center for International Blood and Marrow Transplant Research Chronic Graft-versus-Host Disease Risk Score Predicts Mortality in an Independent Validation Cohort.
- Author
-
Arora, Mukta, Hemmer, Michael T., Kwang Woo Ahn, Klein, John P., Cutler, Corey S., Urbano-Ispizua, Alvaro, Couriel, Daniel R., Alousi, Amin M., Gale, Robert Peter, Yoshihiro Inamoto, Weisdorf, Daniel J., Peigang Li, Antin, Joseph H., Bolwell, Brian J., Boyiadzis, Michael, Cahn, Jean-Yves, Cairo, Mitchell S., Isola, Luis M., Jacobsohn, David A., and Jagasia, Madan
- Subjects
- *
BONE marrow transplantation , *GRAFT versus host disease , *HEALTH outcome assessment , *HEMATOPOIETIC stem cell transplantation , *DISEASE incidence - Abstract
We previously reported a risk score that predicted mortality in patients with chronic graft-versus-host disease (CGVHD) after hematopoietic stem cell transplantation (HCT) between 1995 and 2004 and reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). We sought to validate this risk score in an independent CIBMTR cohort of 1128 patients with CGVHD who underwent transplantation between 2005 and 2007 using the same inclusion criteria and risk score calculations. According to the sum of the overall risk score (range, 1 to 12), patients were assigned to 4 risk groups (RGs): RG1 (0 to 2), RG2 (3 to 6), RG3 (7 to 8), and RG4 (9 to 10). RG3 and RG4 were combined, as RG4 accounted for only 1% of the total cohort. Cumulative incidences of nonrelapse mortality (NRM) and probability of overall survival were significantly different between each RG (all P < .01). NRM and overall survival at 5 years after CGVHD for each RG were 17% and 72% in RG1, 26% and 53% in RG2, and 44% and 25% in RG3, respectively (all P < .01). Our study validates the prognostic value of the CIBMTR CGVHD RGs for overall survival and NRM in a contemporary transplantation population. The CIBMTR CGVHD RGs can be used to predict major outcomes, tailor treatment planning, and enroll patients in clinical trials. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
14. Unrelated Donor Allogeneic Transplantation after Failure of Autologous Transplantation for Acute Myelogenous Leukemia: A Study from the Center for International Blood and Marrow Transplantation Research.
- Author
-
Foran, James M., Pavletic, Steven Z., Logan, Brent R., Agovi-Johnson, Manza A., Pérez, Waleska S., Bolwell, Brian J., Bornhäuser, Martin, Bredeson, Christopher N., Cairo, Mitchell S., Camitta, Bruce M., Copelan, Edward A., Dehn, Jason, Gale, Robert P., George, Biju, Gupta, Vikas, Hale, Gregory A., Lazarus, Hillard M., Litzow, Mark R., Maharaj, Dipnarine, and Marks, David I.
- Subjects
- *
ORGAN donors , *HOMOGRAFTS , *MYELOID leukemia , *AUTOTRANSPLANTATION , *MEDICAL research , *HEALTH outcome assessment - Abstract
Abstract: The survival of patients with relapsed acute myelogenous leukemia (AML) after autologous hematopoietic stem cell transplantation (auto-HCT) is very poor. We studied the outcomes of 302 patients who underwent secondary allogeneic hematopoietic cell transplantation (allo-HCT) from an unrelated donor (URD) using either myeloablative (n = 242) or reduced-intensity conditioning (RIC; n = 60) regimens reported to the Center for International Blood and Marrow Transplantation Research. After a median follow-up of 58 months (range, 2 to 160 months), the probability of treatment-related mortality was 44% (95% confidence interval [CI], 38%-50%) at 1-year. The 5-year incidence of relapse was 32% (95% CI, 27%-38%), and that of overall survival was 22% (95% CI, 18%-27%). Multivariate analysis revealed a significantly better overal survival with RIC regimens (hazard ratio [HR], 0.51; 95% CI, 0.35-0.75; P <.001), with Karnofsky Performance Status score ≥90% (HR, 0.62; 95% CI, 0.47-0.82: P = .001) and in cytomegalovirus-negative recipients (HR, 0.64; 95% CI, 0.44-0.94; P = .022). A longer interval (>18 months) from auto-HCT to URD allo-HCT was associated with significantly lower riak of relapse (HR, 0.19; 95% CI, 0.09-0.38; P <.001) and improved leukemia-free survival (HR, 0.53; 95% CI, 0.34-0.84; P = .006). URD allo-HCT after auto-HCT relapse resulted in 20% long-term leukemia-free survival, with the best results seen in patients with a longer interval to secondary URD transplantation, with a Karnofsky Performance Status score ≥90%, in complete remission, and using an RIC regimen. Further efforts to reduce treatment-related mortaility and relapse are still needed. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
15. Plerixafor Plus Granulocyte Colony-Stimulating Factor Improves the Mobilization of Hematopoietic Stem Cells in Patients with Non-Hodgkin Lymphoma and Low Circulating Peripheral Blood CD34+ Cells
- Author
-
Maziarz, Richard T., Nademanee, Auayporn P., Micallef, Ivana N., Stiff, Patrick J., Calandra, Gary, Angell, Jennifer, DiPersio, John F., and Bolwell, Brian J.
- Subjects
- *
IMMUNOLOGICAL adjuvants , *GRANULOCYTE-colony stimulating factor , *HEMATOPOIETIC stem cells , *LYMPHOMAS , *CD34 antigen , *RANDOMIZED controlled trials , *HEMAPHERESIS , *PATIENTS - Abstract
Abstract: Many institutions have adopted algorithms based on preapheresis circulating CD34+ cell counts to optimize the use of plerixafor. However, a circulating peripheral blood CD34+ cell threshold that predicts mobilization failure has not been defined. The superiority of plerixafor + granulocyte colony-stimulating factor (G-CSF) over placebo + G-CSF for hematopoietic stem cell mobilization and collection was shown for patients with non-Hodgkin lymphoma in a phase III, prospective, randomized, controlled study. The question remains as to which patients may benefit most from the use of plerixafor. In this post hoc retrospective analysis, mobilization outcomes were compared between the 2 treatment arms in patients stratified by peripheral blood CD34+ cell count (<5, 5 to 9, 10 to 14, 15 to 19, or ≥20 cells/μL) obtained before study treatment and apheresis. Compared with placebo plus G-CSF, plerixafor plus G-CSF significantly increased the peripheral blood CD34+ cells/μL over prior day levels in all 5 stratified groups. The probability of subsequent transplantation without a rescue mobilization was far greater in the plerixafor-treated patients for the lowest initial (day 4) peripheral blood CD34+ cells/μL groups (<5, 5 to 9, or 10 to 14). Engraftment and durability were the same for the 2 treatment groups for all strata, but the effect in the lower strata could be altered by the addition of cells from rescue mobilizations. These findings may provide insight into the optimal use of plerixafor in all patients undergoing stem cell mobilization. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
16. Plerixafor Plus Granulocyte Colony-Stimulating Factor versus Placebo Plus Granulocyte Colony-Stimulating Factor for Mobilization of CD34+ Hematopoietic Stem Cells in Patients with Multiple Myeloma and Low Peripheral Blood CD34+ Cell Count: Results of a Subset Analysis of a Randomized Trial
- Author
-
Nademanee, Auayporn P., DiPersio, John F., Maziarz, Richard T., Stadtmauer, Edward A., Micallef, Ivana N., Stiff, Patrick J., Hsu, Frank J., Bridger, Gary, and Bolwell, Brian J.
- Subjects
- *
GRANULOCYTE-colony stimulating factor , *HEMATOPOIETIC stem cell transplantation , *MULTIPLE myeloma , *IMMUNOLOGICAL adjuvants , *GRANULOCYTE colony stimulating factor receptor , *PLACEBOS , *HEMAPHERESIS - Abstract
Preapheresis peripheral blood (PB) CD34+ cell count is a strong predictor of hematopoietic stem cell (HSC) mobilization and is routinely used to optimize the timing, cost, and success of HSC collection in patients with multiple myeloma. However, a uniform PB CD34+ cell count that predicts mobilization failure has not been defined, resulting in the development of institute-specific algorithms for mobilization, particularly regarding the decision of when to use the novel stem cell mobilization agent plerixafor. In this post hoc analysis, we evaluated the mobilization efficacy of plerixafor plus granulocyte colony-stimulating factor (G-CSF) versus placebo plus G-CSF in patients with multiple myeloma, stratified by preapheresis PB CD34+ cell count: <10, <15, <20, and ≥20 cells/μL. Regardless of the PB CD34+ cell count, the total yield of CD34+ cells from apheresis was significantly higher in the plerixafor group than in the placebo group, and significantly more patients in the plerixafor group collected the minimum (≥2 × 106 cells/kg) and optimum (≥6 × 106 cells/kg) stem cell yields on each day of apheresis. As a corollary, the greater stem cell collection in plerixafor-treated patients resulted in the need for significantly fewer days of apheresis to reach minimum and optimum cell doses across all cell count groups. For all CD34+ cell count groups, the proportion of patients proceeding to transplantation and the median time to platelet and neutrophil engraftment were similar in the plerixafor and placebo groups. Our findings demonstrate that in patients with multiple myeloma who might be predicted to fail mobilization based on low PB CD34+ cell count, the addition of plerixafor to G-CSF allows for collection of the minimal and optimal cell doses in a greater proportion of patients compared with G-CSF alone. In addition, plerixafor plus G-CSF significantly improves the likelihood of optimal HSC collection in patients with higher preapheresis PB CD34+ cell counts (≥20 cells/μL) compared with placebo plus G-CSF. Collectively, this analysis of predicted poor mobilizers validates the superiority of plerixafor plus G-CSF compared with G-CSF alone, which had been demonstrated previously in the overall patient population. [Copyright &y& Elsevier]
- Published
- 2012
- Full Text
- View/download PDF
17. Transplanted CD34+ Cell Dose Is Associated with Long-Term Platelet Count Recovery following Autologous Peripheral Blood Stem Cell Transplant in Patients with Non-Hodgkin Lymphoma or Multiple Myeloma
- Author
-
Stiff, Patrick J., Micallef, Ivana, Nademanee, Auayporn P., Stadtmauer, Edward A., Maziarz, Richard T., Bolwell, Brian J., Bridger, Gary, Marulkar, Sachin, Hsu, Frank J., and DiPersio, John F.
- Subjects
- *
HEMATOPOIETIC stem cells , *STEM cell transplantation , *BLOOD platelets , *HODGKIN'S disease , *RED blood cell transfusion , *DATA analysis , *NEUTROPHILS - Abstract
Autologous hematopoietic stem cell transplantation (ASCT) is an established treatment for patients with hematologic malignancies, yet the impact of transplanted CD34+ cell dose on clinical outcomes is unresolved. We conducted post hoc analyses of transplanted CD34+ cell dose and hematopoietic recovery following ASCT in 438 patients with non-Hodgkin lymphoma (NHL) or multiple myeloma (MM), using data from 2 multicenter phase 3 clinical studies that compared plerixafor plus granulocyte-colony stimulating factor (G-CSF) versus placebo plus G-CSF as stem cell mobilization regimens. Days to engraftment and the proportion of patients who reached predetermined blood count thresholds were compared across 3 CD34+ cell dose levels: 2-4 × 106 cells/kg, 4-6 × 106 cells/kg, and >6 × 106 cells/kg, regardless of mobilization treatment. Short-term neutrophil and platelet engraftment times were similar regardless of cell dose. A significant linear trend was observed between transplanted CD34+ cell dose and the proportion of patients with platelet count >150 × 109/L at 100 days (P < .001), 6 months (P = .026), and 12 months (P = .020) in patients with NHL, and at 100 days in patients with MM (P = .004). A linear trend was also observed between transplanted cell dose and the proportion of patients with platelet count >100 × 109/L at 100 days (P < .001) and 6 months (P = .023) in patients with NHL. A higher cell dose was associated with a lower percentage of NHL patients requiring red blood cell transfusions (P = .006). Our analyses confirm previous findings that transplanted CD34+ cell dose may be associated with better long-term platelet recovery after ASCT. [Copyright &y& Elsevier]
- Published
- 2011
- Full Text
- View/download PDF
18. Obesity Does Not Preclude Safe and Effective Myeloablative Hematopoietic Cell Transplantation (HCT) for Acute Myelogenous Leukemia (AML) in Adults
- Author
-
Navarro, Willis H., Agovi, Manza-A., Logan, Brent R., Ballen, Karen, Bolwell, Brian J., Frangoul, Haydar, Gupta, Vikas, Hahn, Theresa, Ho, Vincent T., Juckett, Mark, Lazarus, Hillard M., Litzow, Mark R., Liesveld, Jane L., Moreb, Jan S., Marks, David I., McCarthy, Philip L., Pasquini, Marcelo C., and Rizzo, J. Douglas
- Subjects
- *
HEMATOPOIETIC stem cell transplantation , *MYELOID leukemia , *OBESITY , *BODY mass index , *HEALTH outcome assessment , *COMPARATIVE studies , *CANCER relapse , *MULTIVARIATE analysis - Abstract
The incidence of excessive adiposity is increasing worldwide, and is associated with numerous adverse health outcomes. We compared outcomes by body mass index (BMI) for adult patients with acute myelogenous leukemia (AML) who underwent autologous (auto, n = 373), related donor (RD, n = 2041), or unrelated donor (URD, n = 1801) allogeneic myeloablative hematopoietic cell transplantation (HCT) using bone marrow or peripheral blood stem cells reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1995 to 2004. Four weight groups by BMI (kg/m2) were defined: underweight <18 kg/m2; normal 18-25 kg/m2; overweight >25-30 kg/m2; and obese >30 kg/m2. Multivariable analysis referenced to the normal weight group showed an increased risk of death for underweight patients in the RD group (relative risk [RR], 1.92; 95% confidence interval [CI], 1.28-2.89; P = .002), but not in the URD group. There were no other differences in outcomes among the other weight groups within the other HCT groups. Overweight and obese patients enjoyed a modest decrease in relapse incidence, although this did not translate into a survival benefit. Small numbers of patients limit the ability to better characterize the adverse outcomes seen in the underweight RD but not the underweight URD allogeneic HCT patients. Obesity alone should not be considered a barrier to HCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
19. Allogeneic Hematopoietic Cell Transplant for Prolymphocytic Leukemia
- Author
-
Kalaycio, Matt E., Kukreja, Manisha, Woolfrey, Ann E., Szer, Jeffrey, Cortes, Jorge, Maziarz, Richard T., Bolwell, Brian J., Buser, Andreas, Copelan, Edward, Gale, Robert Peter, Gupta, Vikas, Maharaj, Dipnarine, Marks, David I., Pavletic, Steven Z., Horowitz, Mary M., and Arora, Mukta
- Subjects
- *
HEMATOPOIETIC stem cells , *STEM cell transplantation , *HOMOGRAFTS , *LEUKEMIA treatment , *BONE marrow transplantation , *DISEASE progression , *FACTOR analysis - Abstract
The poor prognosis of patients with prolymphocytic leukemia (PLL) has led some clinicians to recommend allogeneic hematopoietic cell transplant (HCT). However, the data to support this approach is limited to case-reports and small case series. We reviewed the database of the Center for International Blood and Marrow Transplant Research (CIBMTR) to determine outcomes after allotransplant for patients with PLL. We identified 47 patients with a median age of 54 years (range: 30-75 years). With a median follow-up of 13 months, progression-free survival (PFS) was 33% (95% confidence interval [CI] 20%-47%) at 1 year. The most common cause of death was relapse or progression in 49%. The cumulative incidence of treatment-related mortality (TRM) at 1-year posttransplant was 28%. The small patient population prohibited prognostic factor analysis, but these data support consideration of allotransplant for PLL. Further study of a larger population of patients is needed to determine which patients are more likely to benefit. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
20. Outcome of Transplantation for Myelofibrosis
- Author
-
Ballen, Karen K., Shrestha, Smriti, Sobocinski, Kathleen A., Zhang, Mei-Jie, Bashey, Asad, Bolwell, Brian J., Cervantes, Francisco, Devine, Steven M., Gale, Robert Peter, Gupta, Vikas, Hahn, Theresa E., Hogan, William J., Kröger, Nicolaus, Litzow, Mark R., Marks, David I., Maziarz, Richard T., McCarthy, Philip L., Schiller, Gary, Schouten, Harry C., and Roy, Vivek
- Subjects
- *
MYELOFIBROSIS , *STEM cell transplantation , *HEMATOPOIETIC stem cells , *HOMOGRAFTS , *HLA histocompatibility antigens , *GRAFT versus host disease , *THERAPEUTICS - Abstract
Myelofibrosis is a myeloproliferative disorder incurable with conventional strategies. Several small series have reported long-term disease-free survival (DSF) after allogeneic hematopoietic cell transplantation (HCT). In this study, we analyze the outcomes of 289 patients receiving allogeneic transplantation for primary myelofibrosis between 1989 and 2002, from the database of the Center for International Bone Marrow Transplant Research (CIBMTR). The median age was 47 years (range: 18-73 years). Donors were HLA identical siblings in 162 patients, unrelated individuals in 101 patients, and HLA nonidentical family members in 26 patients. Patients were treated with a variety of conditioning regimens and graft-versus-host disease (GVHD) prophylaxis regimens. Splenectomy was performed in 65 patients prior to transplantation. The 100-day treatment-related mortality was 18% for HLA identical sibling transplants, 35% for unrelated transplants, and 19% for transplants from alternative related donors. Corresponding 5-year overall survival (OS) rates were 37%, 30%, and 40%, respectively. DFS rates were 33%, 27%, and 22%, respectively. DFS for patients receiving reduced-intensity transplants was comparable: 39% for HLA identical sibling donors and 17% for unrelated donors at 3 years. In this large retrospective series, allogeneic transplantation for myelofibrosis resulted in long-term relapse-free survival (RFS) in about one-third of patients. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
21. A Comparison of HLA-Identical Sibling Allogeneic versus Autologous Transplantation for Diffuse Large B Cell Lymphoma: A Report from the CIBMTR
- Author
-
Lazarus, Hillard M., Zhang, Mei-Jie, Carreras, Jeanette, Hayes-Lattin, Brandon M., Ataergin, Asli Selmin, Bitran, Jacob D., Bolwell, Brian J., Freytes, César O., Gale, Robert Peter, Goldstein, Steven C., Hale, Gregory A., Inwards, David J., Klumpp, Thomas R., Marks, David I., Maziarz, Richard T., McCarthy, Philip L., Pavlovsky, Santiago, Rizzo, J. Douglas, Shea, Thomas C., and Schouten, Harry C.
- Subjects
- *
HODGKIN'S disease , *BONE marrow transplant complications , *COHORT analysis , *AUTOTRANSPLANTATION , *HEALTH outcome assessment , *MORTALITY - Abstract
We compared outcomes of 916 diffuse large B cell lymphoma (DLBCL) patients aged ≥18 years undergoing first autologous (n = 837) or myeloablative (MA) allogeneic hematopoietic cell transplant (HCT) (n = 79) between 1995 and 2003 reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). Median follow-up was 81 months for allogeneic HCT versus 60 months for autologous HCT. Allogeneic HCT recipients were more likely to have high-risk disease features including higher stage, more prior chemotherapy regimens, and resistant disease. Allogeneic HCT was associated with a higher 1 year treatment-related mortality (TRM) (relative risk [RR] 4.88, 95% confidence interval [CI], 3.21-7.40, P < .001), treatment failure (RR 2.06, 95% CI, 1.54-2.75, P < .001), and mortality (RR 2.75, 95% CI, 2.03-3.72, P < .001). Risk of disease progression was similar in the 2 groups (RR 1.12, 95% CI, 0.73-1.72, P = .59). In fact, for 1-year survivors, no significant differences were observed for TRM, progression, progression-free (PFS) or overall survival (OS). Increased risks of TRM and mortality were associated with older age (>50 years), lower performance score, chemoresistance, and earlier year of transplant. In a cohort of mainly high-risk DLBCL patients, upfront MA allogeneic HCT, although associated with increased early mortality, was associated with a similar risk of disease progression compared to lower risk patients receiving autologous HCT. [Copyright &y& Elsevier]
- Published
- 2010
- Full Text
- View/download PDF
22. Impact of Pre-transplant Rituximab on Survival after Autologous Hematopoietic Stem Cell Transplantation for Diffuse Large B Cell Lymphoma
- Author
-
Fenske, Timothy S., Hari, Parameswaran N., Carreras, Jeanette, Zhang, Mei-Jie, Kamble, Rammurti T., Bolwell, Brian J., Cairo, Mitchell S., Champlin, Richard E., Chen, Yi-Bin, Freytes, César O., Gale, Robert Peter, Hale, Gregory A., Ilhan, Osman, Khoury, H. Jean, Lister, John, Maharaj, Dipnarine, Marks, David I., Munker, Reinhold, Pecora, Andrew L., and Rowlings, Philip A.
- Subjects
- *
RITUXIMAB , *AUTOGRAFTS , *STEM cell transplantation , *HEMATOPOIETIC stem cells , *LYMPHOMA treatment , *B cells , *MONOCLONAL antibody probes , *SALVAGE therapy - Abstract
Incorporation of the anti-CD20 monoclonal antibody rituximab into front-line regimens to treat diffuse large B cell lymphoma (DLBCL) has resulted in improved survival. Despite this progress, however, many patients develop refractory or recurrent DLBCL and then undergo autologous hematopoietic stem cell transplantation (AuHCT). It is unclear to what extent pre-transplant exposure to rituximab affects outcomes after AuHCT. Outcomes of 994 patients receiving AuHCT for DLBCL between 1996 and 2003 were analyzed according to whether rituximab was (n = 176; +R cohort) or was not (n = 818; −R cohort) administered with front-line or salvage therapy before AuHCT. The +R cohort had superior progression-free survival (PFS; 50% vs 38%; P = .008) and overall survival (OS; 57% vs 45%; P = .006) at 3 years. Platelet and neutrophil engraftment were not affected by exposure to rituximab. Nonrelapse mortality (NRM) did not differ significantly between the 2 cohorts. In multivariate analysis, the +R cohort had improved PFS (relative risk of relapse/progression or death, 0.64; P < .001) and improved OS (relative risk of death, 0.74; P = .039). We conclude that pre-transplant rituximab is associated with a lower rate of progression and improved survival after AuHCT for DLBCL, with no evidence of impaired engraftment or increased NRM. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
23. Late Mortality and Relapse following BuCy2 and HLA-Identical Sibling Marrow Transplantation for Chronic Myelogenous Leukemia
- Author
-
Copelan, Edward A., Crilley, Pamela Ann, Szer, Jeffrey, Dodds, Anthony J., Stevenson, Dustin, Phillips, Gary, Elder, Patrick, Nivison-Smith, Ian, Avalos, Belinda R., Penza, Sam, Topolsky, David, Sobecks, Ronald, Kalaycio, Matt, and Bolwell, Brian J.
- Subjects
- *
MORTALITY , *DISEASE relapse , *HLA histocompatibility antigens , *STEM cell transplantation , *DRUG therapy , *HEMATOPOIETIC stem cells , *TREATMENT of chronic myeloid leukemia - Abstract
Allogeneic hematopoietic stem cell transplantation (HSCT) is the only known curative therapy for chronic myelogenous leukemia (CML). Failure, because of relapse or nonrelapse mortality (NRM), generally occurs within 3 years of transplantation, but large studies with long-term follow-up are limited. We present mature results in 335 patients with CML who underwent allogeneic bone marrow transplantation (BMT) from HLA-identical siblings following busulfan and cyclophosphamide (BU/Cy2). Two hundred twenty-nine were in chronic phase (CP) and 106 in accelerated or blastic phase at transplantation. Median follow-up exceeded 14 years. The estimated probability of 18-year leukemia-free survival (LFS) for CP patients was 55.6% and for those beyond CP, 10.5%. Of 182 patients who survived leukemia-free at 3 years, the estimated probability of LFS at 18 years was 61.9%. Late relapse (P = .039) and late NRM (P = .008) occurred at higher rates in patients beyond CP at transplantation. There was no plateau in LFS. [Copyright &y& Elsevier]
- Published
- 2009
- Full Text
- View/download PDF
24. Influence of Age and Histology on Outcome in Adult Non-Hodgkin Lymphoma Patients Undergoing Autologous Hematopoietic Cell Transplantation (HCT): A Report from The Center For International Blood & Marrow Transplant Research (CIBMTR)
- Author
-
Lazarus, Hillard M., Carreras, Jeanette, Boudreau, Christian, Loberiza, Fausto R., Armitage, James O., Bolwell, Brian J., Freytes, César O., Gale, Robert Peter, Gibson, John, Hale, Gregory A., Inwards, David J., LeMaistre, Charles F., Maharaj, Dipnarine, Marks, David I., Miller, Alan M., Pavlovsky, Santiago, Schouten, Harry C., van Besien, Koen, Vose, Julie M., and Bitran, Jacob D.
- Subjects
- *
HODGKIN'S disease , *CELL transplantation , *HEMATOPOIETIC stem cells , *BONE marrow transplantation , *HEALTH outcome assessment , *MULTIVARIATE analysis , *MEDICAL care research , *PATIENTS - Abstract
Abstract: To compare the clinical outcomes of older (age ≥55 years) non-Hodgkin lymphoma (NHL) patients with younger NHL patients (<55 years) receiving autologous hematopoietic cell transplantation (HCT) while adjusting for patient-, disease-, and treatment-related variables, we compared autologous HCT outcomes in 805 NHL patients aged ≥55 years to 1949 NHL patients <55 years during the years 1990–2000 using data reported to the Center for International Blood and Marrow Transplant Research (CIBMTR). In multivariate analysis, older patients with aggressive histologies were 1.86 times (95% confidence interval [CI] 1.43-2.43, P < .001) more likely than younger patients to experience treatment-related mortality (TRM). Relative death risks were 1.33 times (CI 1.04-1.71, P = .024) and 1.50 times (CI 1.33-16.9, P < .001) higher in older compared to younger patients with follicular grade I/II and aggressive histologies, respectively. Autologous HCT in older NHL patients is feasible, but most disease-related outcomes are statistically inferior to younger patients. Studies addressing supportive care particular to older patients, who are most likely to benefit from this approach, are recommended. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
25. Allogeneic Transplants in Follicular Lymphoma: Higher Risk of Disease Progression after Reduced-Intensity Compared to Myeloablative Conditioning
- Author
-
Hari, Parameswaran, Carreras, Jeanette, Zhang, Mei-Jie, Gale, Robert Peter, Bolwell, Brian J., Bredeson, Christopher N., Burns, Linda J., Cairo, Mitchell S., Freytes, César O., Goldstein, Steven C., Hale, Gregory A., Inwards, David J., LeMaistre, Charles F., Maharaj, Dipnarine, Marks, David I., Schouten, Harry C., Slavin, Shimon, Vose, Julie M., Lazarus, Hillard M., and van Besien, Koen
- Subjects
- *
STEM cells , *CELLULAR therapy , *DRUG therapy , *BLOOD cells - Abstract
Abstract: Reduced-intensity conditioning (RIC) regimens have been increasingly used for allogeneic hematopoietic stem cell transplantation (HSCT) in follicular lymphoma (FL). We compared traditional myeloablative conditioning regimens to RIC in FL. Outcomes of HLA-identical sibling HSCT for FL in 208 recipients reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) between 1997 and 2002 were studied. Conditioning regimens were categorized as myeloablative (N = 120) or RIC (N = 88). Use of RIC regimens increased from <10% of transplants in 1997 to >80% in 2002 signaling a major shift in practice. Patients receiving RIC were older and had a longer interval from diagnosis to transplant. These differences did not correlate with outcomes. Median follow-up of survivors was 50 months (4-96 months) after myeloablative conditioning versus 35 months (4-82 months) after RIC (P < .001). At 3 years, overall survival (OS) for the myeloablative and RIC cohorts were 71 (63%-79%) and 62 (51%-72%; P = .15) and progression free survival (PFS), 67 (58%-75%) and 55 (44%-65%; P = .07), respectively. Lower Karnofsky performance score (KPS) and resistance to chemotherapy were associated with higher treatment-related mortality (TRM) and lower OS and PFS. On multivariate analysis, an increased risk of lymphoma progression after RIC was observed (relative risk = 2.97, P = .04). RIC has become the de facto standard in allogeneic HSCT for FL, and appears to result in similar long-term outcomes. Although disease-free survival (DPS) is similar compared to myeloablative conditioning, an increased risk of late disease progression after RIC is concerning. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
26. HLA-Identical Sibling Allogeneic Transplants versus Chemotherapy in Acute Myelogenous Leukemia with t(8;21) in First Complete Remission: Collaborative Study between the German AML Intergroup and CIBMTR
- Author
-
Schlenk, Richard F., Pasquini, Marcelo C., Pérez, Waleska S., Zhang, Mei-Jie, Krauter, Jürgen, Antin, Joseph H., Bashey, Asad, Bolwell, Brian J., Büchner, Thomas, Cahn, Jean-Yves, Cairo, Mitchell S., Copelan, Edward A., Cutler, Corey S., Döhner, Hartmut, Gale, Robert Peter, Ilhan, Osman, Lazarus, Hillard M., Liesveld, Jane L., Litzow, Mark R., and Marks, David I.
- Subjects
- *
CELLULAR therapy , *CELL transplantation , *HEMATOPOIETIC stem cells , *DRUG therapy - Abstract
Abstract: We studied the role of HLA-matched sibling hematopoietic cell transplantation (HCT) in treating t(8;21) acute myelogenous leukemia (AML) in first remission. Outcomes of 118 patients receiving HCT and reported to the Center for International Blood and Marrow Transplant Research were compared with 132 similar patients receiving chemotherapy selected from 8 German AML Intergroup multicenter trials. Characteristics of the cohorts were similar except that chemotherapy recipients were significantly older. To adjust for time to treatment bias, outcomes were compared using left-truncated Cox regression models. Transplants were associated with higher treatment-related mortality (TRM; relative risk [RR] 6.76, 95% confidence interval [CI] 2.95-15.45, P < .001), lower relapse (RR 0.47, 95% CI 0.25-0.85, P = .01), and similar relapse-free survival (P = .2). Loss of sex chromosomes (LOS) in addition to t(8;21) had a negative impact on overall survival (OS) in patients receiving chemotherapy. Patients without LOS experienced shorter survival after HCT comparing to chemotherapy (RR 3.05, P = .02), whereas patients with LOS had similar survival regardless of postremission therapy. In both cohorts, white blood cell count (WBC) at diagnosis >25 × 109/L was associated with a higher relapse risk (RR = 2.09, P = .03), lower relapse-free (RR = 1.9, P = .008), and OS (RR = 1.91, P = .01). In this cohort of patients with t(8;21) AML, HCT did not improve OS, because reduction of relapse was offset by high TRM. In the group without LOS, survival after chemotherapy was far superior to HCT. These results suggest that patients with t(8;21) AML without poor prognostic factors have higher rates of survival after chemotherapy as a post remission therapy compared to HCT. [Copyright &y& Elsevier]
- Published
- 2008
- Full Text
- View/download PDF
27. Utility of Single versus Tandem Autotransplants for Advanced Testes/Germ Cell Cancer: A Center for International Blood and Marrow Transplant Research (CIBMTR) Analysis
- Author
-
Lazarus, Hillard M., Stiff, Patrick J., Carreras, Jeanette, Logan, Brent R., Akard, Luke, Bolwell, Brian J., Childs, Richard W., Gale, Robert Peter, Klein, John P., Lill, Michael C., Pérez, Waleska S., Stadtmauer, Edward A., and Rizzo, J. Douglas
- Subjects
- *
CANCER patients , *ENDOCRINE glands , *GERMPLASM , *AUTOGRAFTS - Abstract
Abstract: Tandem autotransplants are used to treat advanced testis cancer patients but their value compared to a single autotransplant is unknown. To evaluate the results of autotransplant in relapsed testicular/germ cell cancer, data from 300 patients undergoing autotransplants 1989-2002 were reported to the Center for International Blood and Marrow Transplant Research. We compared results for those patients intended to undergo tandem autotransplant procedures (N = 102) versus patients in whom a second autotransplant was not planned (N = 198). Five-year survival probability was 35% (95% confidence interval = 25%-46%) in the planned tandem transplant cohort compared to 42% (35%-49%) in the group not planned to have a second transplant (P = .29). Probability of progression-free survival at 5 years for these cohorts was 34% (25%-44%) and 38% (31%-45%), respectively (P = .50). The planned tandem autotransplant cohort had significantly more advanced disease at diagnosis and greater likelihood of cisplatin resistance. Patients intended to receive tandem transplants had a lower treatment-related mortality at 1 year (3% versus 10%, P = .02). Using propensity score analysis the planned tandem autotransplant cohort had significantly lower treatment-related mortality (P = .044) but no different risk of relapse (P = .541) compared to the planned single transplant cohort. Tandem autotransplants for testicular cancer are associated with less treatment-related mortality than a planned single transplant, with no differences in disease-related outcomes or overall survival at 3 years. Patient selection bias for either transplant approach, however, may affect the results of this observational study; a randomized trial is needed to determine which approach, if either, is better. [Copyright &y& Elsevier]
- Published
- 2007
- Full Text
- View/download PDF
28. ABO Blood Group Barrier in Allogeneic Bone Marrow Transplantation Revisited
- Author
-
Seebach, Jörg D., Stussi, Georg, Passweg, Jakob R., Loberiza, Fausto R., Gajewski, James L., Keating, Armand, Goerner, Martin, Rowlings, Philip A., Tiberghien, Pierre, Elfenbein, Gerald J., Gale, Robert Peter, van Rood, Jon J., Reddy, Vijay, Gluckman, Eliane, Bolwell, Brian J., Klumpp, Thomas R., Horowitz, Mary M., Ringdén, Olle, and Barrett, A. John
- Subjects
- *
BONE marrow transplantation , *IMMUNE system , *LEUKEMIA , *GRAFT versus host disease - Abstract
Abstract: Reports have shown a worse outcome for donor-recipient pairs mismatched for ABO blood groups in bone marrow transplantation (BMT). These studies, however, included small and heterogenous study populations, and not all considered bidirectional ABO incompatibility separately. Because the issue remains controversial, we analyzed the effect of ABO mismatch on the overall survival, transplant-related mortality, and occurrence of acute and chronic graft-versus-host disease (GVHD) in a large homogenous group of patients undergoing allogeneic BMT. A total of 3103 patients with early-stage leukemia who underwent transplantation between 1990 and 1998 with bone marrow from an HLA-identical sibling and who were reported to the Center for International Blood and Marrow Transplant Research were studied. The median follow-up was 54 months. A total of 2108 (67.9%) donor-recipient pairs were ABO identical, 451 (14.5%) had a minor mismatch, 430 (13.9%) had a major mismatch, and 114 (3.7%) had a bidirectional ABO mismatch. The groups did not differ significantly in patient or donor characteristics except for more female-to-male sex mismatch in the bidirectional ABO mismatch group (P = .017). In multivariate models of overall survival, transplant-related mortality, and grade II to IV acute GVHD, there were no significant differences among the 4 groups. Bidirectional ABO mismatch was associated with a significantly higher risk of grade III or IV acute GVHD (hazard ratio, 1.869; 95% confidence interval, 1.192-2.93; P = .006). Patients with major ABO mismatch received red blood cell transfusions (P = .001) for a longer timer after transplantation and had a slightly slower neutrophil recovery (P < .001). There was no evidence of a substantial effect of ABO blood group incompatibility on the outcome of conventional BMT among patients with leukemia. [Copyright &y& Elsevier]
- Published
- 2005
- Full Text
- View/download PDF
29. Molecular TCR diagnostics can be used to identify shared clonotypes after allogeneic hematopoietic stem cell transplantation
- Author
-
O'Keefe, Christine L., Sobecks, Ronald M., Wlodarski, Mercin, Rodriguez, Alexander, Bell, Kimberly, Kuczkowski, Elizabeth, Bolwell, Brian J., and Maciejewski, Jaroslaw P.
- Subjects
- *
LYMPHOCYTES , *T cells , *STEM cells , *IMMUNOSUPPRESSION - Abstract
In allogeneic hematopoietic stem cell (HSCT) transplantation, recovery of the T cell receptor (TCR) repertoire depends upon the composition of the graft and is modulated by peri-transplant immunosuppression, viral infections, and graft-vs-host disease (GVHD). We hypothesized that after allogeneic HSCT, molecular analysis of the TCR repertoire can be used to identify and quantitate immunodominant T cell clones that may play a role in GVHD or other clinical events.We utilized a rational strategy for the analysis of the expanded CTL clones. First, we studied the VB spectrum in a cohort of patients who had received either matched sibling or unrelated donor grafts. The CDR3 sequences of immunodominant clones were identified and clonotypic PCR and sequencing was applied to determine the level of clonotype sharing.Significant expansions of VB families were observed following transplantations; 61% were oligo/monoclonal. Immunodeficiency was reflected by depletion of multiple VB families from both the CD8 and CD4 repertoires. The level of sharing varied between clonotypes, suggesting that some antigens have a more “public” spectrum while others are restricted to specific patients. Immunodominant CDR3 sequences common to allogeneic HSCT, healthy controls, and other conditions were identified.The clonotypes of expanded CTL clones may reflect responses to alloantigens (e.g., in correlation with clinical GVHD) or pathogens. In the future, molecular T cell diagnostics may become a powerful clinical tool in transplantation to monitor disease and to direct treatment. [Copyright &y& Elsevier]
- Published
- 2004
- Full Text
- View/download PDF
30. A phase III, randomized, double-blind, placebo-controlled, study of iseganan for the reduction of stomatitis in patients receiving stomatotoxic chemotherapy
- Author
-
Giles, Francis J., Rodriguez, Roberto, Weisdorf, Daniel, Wingard, John R., Martin, Paul J., Fleming, Thomas R., Goldberg, Stuart L., Anaissie, Elias J., Bolwell, Brian J., Chao, Nelson J., Shea, Thomas C., Brunvand, Mark M., Vaughan, William, Petersen, Finn, Schubert, Mark, Lazarus, Hillard M., Maziarz, Richard T., Silverman, Margarida, Beveridge, Roy A., and Redman, Rebecca
- Subjects
- *
PLACEBOS , *STOMATITIS , *DRUG therapy , *PATHOLOGICAL physiology - Abstract
The invasion and colonization of oral cavity mucosal tissues by microflora may contribute to the pathophysiology of ulcerative oral mucositis (UOM). Iseganan is an analog of protegrin-1, a naturally occurring peptide with broad-spectrum microbicidal activity. A randomized, double-blind, placebo-controlled study was conducted to evaluate the efficacy and safety of iseganan in preventing UOM after stomatotoxic therapy.Patients received an oral rinse, consisting of iseganan 9 mg or placebo, to be swished/swallowed six times daily, starting with stomatotoxic therapy and continuing up to 21 days. Patients were assessed for stomatitis and UOM, and administered a questionnaire evaluating mouth pain and difficulty swallowing thrice weekly. The primary study efficacy endpoint was the proportion of patients who did not have peak stomatitis NCI-CTC grade ≥2.Between November 2001 and June 2002, 502 patients were randomized to receive iseganan (251) or placebo (251). Equivalent numbers of patients in both cohorts received bone marrow or peripheral blood allogeneic or autologous stem cell transplantation (SCT). Forty-three percent and 37% of iseganan and placebo patients, respectively, did not have peak stomatitis grade =2 (
P=0.182 ). There was no significant difference between the cohorts in stomatitis severity, incidence of UOM, peak mouth pain, peak difficulty swallowing, amount of opiate analgesics used, or adverse event type or incidence.A major impact of Iseganan on reducing stomatitis, UOM, or its clinical sequelae in patients receiving stomatotoxic therapy was not detected on this study. [Copyright &y& Elsevier]- Published
- 2004
- Full Text
- View/download PDF
31. The value of augmented preparative regimens combined with an autologous bone marrow transplant for the management of relapsed or refractory hodgkin disease: A southwest oncology group phase II trial
- Author
-
Stiff, Patrick J., Unger, Joseph M., Forman, Stephen J., McCall, Anne R., LeBlanc, Michael, Nademanee, Auayporn P., Bolwell, Brian J., and Fisher, Richard I.
- Subjects
- *
IRRADIATION , *BONE marrow transplantation , *DRUG therapy , *HODGKIN'S disease - Abstract
Several single-institution pilot studies have suggested that augmented preparative regimens, including those containing total body irradiation combined with an autologous bone marrow transplantation, are superior to standard regimens for the treatment of relapsed or refractory Hodgkin disease. On the basis of these data, we undertook, in the cooperative group setting, a phase II trial of augmented preparative regimens for patients experiencing treatment failure with conventional chemotherapy. Eighty-one patients with either sensitive or refractory (induction failures or chemoresistant) relapse received etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and either total body irradiation (12 Gy) or, if previously irradiated, carmustine (15 mg/kg), followed by an autologous bone marrow transplantation. Progression-free (PFS) and overall (OS) survival were estimated, and a Cox regression model was used to assess potential prognostic variables. The 5-year PFS and OS for the 74 eligible patients treated at 20 Southwest Oncology Group centers were 41% (95% confidence interval [CI], 29%–53%) and 54% (95% CI, 43%–65%), respectively, despite a median remission after initial chemotherapy of only 6 months. The 3-year OS for those whose induction therapy failed was 72% (95% CI, 52%–93%). There was 1 (1.4%) early treatment-related death, 2 late deaths due to lung toxicity, and only 1 death due to myelodysplasia. There were no differences in PFS or OS on the basis of regimen or chemosensitivity. A Cox prognostic factor analysis determined that >2 prior regimens, relapse in a radiated field, and extranodal disease were adverse prognostic factors. Among the 46 patients who received prior radiotherapy, the 5-year OS was 38% (95% CI, 14%–61%) for patients with 2 or 3 adverse factors, versus 60% (95% CI, 42%–78%) for those with 0 factors or 1 adverse factor. Augmented preparative regimens seem promising for the treatment of relapsed or refractory Hodgkin disease, without an increase in regimen-related mortality. A poor-prognosis group was identified that should be treated with novel therapies. [Copyright &y& Elsevier]
- Published
- 2003
- Full Text
- View/download PDF
32. Alternate Donor Hematopoietic Cell Transplantation (HCT) in Non-Hodgkin Lymphoma Using Lower Intensity Conditioning: A Report from the CIBMTR
- Author
-
Hale, Gregory A., Shrestha, Smriti, Le-Rademacher, Jennifer, Burns, Linda J., Gibson, John, Inwards, David J., Freytes, Cesar O., Bolwell, Brian J., Hsu, Jack W., Slavin, Shimon, Isola, Luis, Rizzieri, David A., Gale, Robert Peter, Laport, Ginna G., Montoto, Silvia, Lazarus, Hillard M., and Hari, Parameswaran N.
- Subjects
- *
DRUG therapy , *HEMATOPOIETIC stem cell transplantation , *LYMPHOMAS , *MORTALITY , *HISTOPATHOLOGY , *GLOBULINS - Abstract
We analyzed the outcomes of 248 (61% male) adult recipients of HLA-matched unrelated and HLA-mismatched related donor hematopoietic cell transplantation (HCT) for non-Hodgkin lymphoma (NHL) after reduced or lower intensity conditioning (RIC), reported to the Center for International Blood and Marrow Transplant Research (CIBMTR) from 1997 to 2004. Median age was 52 (range: 18-72 years); 31% had a Karnofsky performance score <90. Follicular NHL (43%) was the major histology. Incidence of grades II-IV acute graft-versus-host disease (aGVHD) was 43% at 100 days; and chronic GVHD (cGVHD) was 44% at 3 years. Treatment-related mortality (TRM) at 100 days was 24%. Three-year overall survival (OS) and progression-free survival (PFS) were 41% and 32%, respectively. In multivariate analysis, use of antithymocyte globulin (ATG) and HLA mismatch were associated with increased TRM. High-grade histology, ATG use, and chemotherapy resistance were associated with lower PFS. Older age, shorter interval from diagnosis to HCT, non–total body irridiation (TBI) conditioning regimens, ex vivo T cell depletion, and HLA-mismatched unrelated donors were associated with mortality. GVHD did not influence relapse or PFS. Older age, aggressive histology, and chemotherapy resistance correlated with poorer survival. For selected patients with NHL, lack of an available sibling donor should not be a barrier to allogeneic HCT. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.